{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018600","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.924399+00:00","generated_at":"2026-05-18T08:43:34.780979+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference","bullets":["CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.","Oral presentation by co-CEO Sam Lee on Sept 11, 2025 at the 9th International Calicivirus Conference in Banff.","Phase 1 study completed evaluating safety, tolerability, pharmacokinetics, and food effect in healthy adults.","No approved vaccine or antiviral exists for norovirus; CDI-988 targets a conserved region of 3CL protease."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018600","json":"https://secwatch.observer/filing/0001641172-25-018600.json","markdown":"https://secwatch.observer/filing/0001641172-25-018600.md","text":"https://secwatch.observer/filing/0001641172-25-018600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/0001641172-25-018600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:43:34.780979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}